Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise The single-dose pen does not require mixing nor ...

The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial. The Food and Drug Administration (FDA) has approved 2 additional dosage strengths of Trulicity ® ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

Eli Lilly and Company (LLY) announced that the FDA granted approval to two higher doses, 3 mg and 4.5 mg, of its GLP-1 receptor agonist, Trulicity. The approval was based on data from the AWARD-11 ...

Results from the phase 3 AWARD-11 trial evaluating higher doses of dulaglutide showed superior HbA1c and body weight reductions with an investigational 4.5mg dose in patients with type 2 diabetes (T2D ...

Older female adult smiling while purchasing some medication after asking does Medicare cover Trulicity Doctors may prescribe drugs like Trulicity to help manage a person’s diabetes, but only certain ...

Diabetes is a huge business for Eli Lilly and Co. The company’s six major diabetes medicines rang up more than $2 billion in worldwide sales last year and are expected to exceed $4 billion by 2020.

- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- ...